Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a dive ...

Johnson & Johnson (NYSE:JNJ) recently announced a 4.8% increase in its quarterly dividend and released positive Phase 3 clinical data for icotrokinra, an oral treatment for plaque psoriasis. These ...

Discover the early warning signs of psoriatic arthritis that could prevent permanent joint damage, plus expert advice on treatment options and daily management.

It is approved for use in rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and adults with chronic moderate-to-severe plaque psoriasis. In clinical ...

I’ve spent a lot more money on products that do a lot less. And I was very hesitant to buy something so inexpensive as I ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Icotrokinra appears to be an effective treatment for adolescents with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

New results from a subgroup analysis of the ICONIC-LEAD study showed icotrokinra was effective and safe for the treatment of moderate to severe plaque psoriasis in adolescents, according to a press ...

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...